Our commitment is to improve the quality of life of patients with epilepsy and cognitive disorders.
What we do
DEVELOPING NEW DRUGS
We identify and develop drug candidates with innovative mechanisms of action. By differentiating our approach from existing treatments, we aim at offering new therapeutic options to patients.
The molecules we develop are lipid derivatives. The robust experience of our team in complex lipid biochemistry enables us to tap the pharmacological potential of these molecules.
GAOMA is a biotech company founded in 2019 and based in Bron, close to Lyon, France. Our team is committed to transform scientific discoveries into adapted therapeutic solutions for patients.
SEED ROUND AND PARTNERSHIP WITH PPRS
ELLIPSE – INNOVATIONS IN EPILEPSY
EILAT XV – 2020 – GAOMA THERAPEUTICS TO PRESENT GAO-3-02 DRUG CANDIDATE